These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 1521913)

  • 21. Imaging pattern of radiolabelled lymphokine-activated killer cells in patients with metastatic malignant melanoma.
    Schäfer E; Dummer R; Eilles C; Börner W; Martin R; Rendl J; Burg G
    Eur J Nucl Med; 1991; 18(2):106-10. PubMed ID: 2044569
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Administration of BiMAb-retargeted T cells in a rat hepatic metastases colon tumour model results in T-cell tumour infiltration independent of the route of administration.
    Koelemij R; Hagenaars M; Ensink NG; Eggermont AM; Van De Velde CJ; Fleuren GJ; Kuppen PJ
    Scand J Immunol; 2001 Mar; 53(3):277-81. PubMed ID: 11251885
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Transcatheter arterial injection of autologous lymphokine-activated killer (LAK) cells into patients with liver cancers.
    Komatsu T; Yamauchi K; Furukawa T; Obata H
    J Clin Immunol; 1990 May; 10(3):167-74. PubMed ID: 2164039
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Adoptive immunotherapy of human pancreatic cancer with lymphokine-activated killer cells and interleukin-2 in a nude mouse model.
    Marincola FM; Da Pozzo LF; Drucker BJ; Holder WD
    Surgery; 1990 Nov; 108(5):919-29. PubMed ID: 2237773
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Change in peripheral blood lymphocyte count in dogs following adoptive immunotherapy using lymphokine-activated T killer cells combined with palliative tumor resection.
    Mie K; Shimada T; Akiyoshi H; Hayashi A; Ohashi F
    Vet Immunol Immunopathol; 2016 Sep; 177():58-63. PubMed ID: 27436446
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Lymphokine-activated killer (LAK) cells can be focused at sites of tumor growth by products of macrophage activation.
    Migliori RJ; Gruber SA; Sawyer MD; Hoffman R; Ochoa A; Bach FH; Simmons RL
    Surgery; 1987 Aug; 102(2):155-62. PubMed ID: 3497459
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Regional administration of natural killer cells in a rat hepatic metastasis model results in better tumor infiltration and anti-tumor response than systemic administration.
    Hagenaars M; Ensink NG; Koelemij R; Basse PH; Eggermont AM; van de Velde CJ; Fleuren GJ; Kuppen PJ
    Int J Cancer; 1998 Jan; 75(2):233-8. PubMed ID: 9462713
    [TBL] [Abstract][Full Text] [Related]  

  • 28. In vivo and in vitro effect of adoptive immunotherapy of experimental murine brain tumors using lymphokine-activated killer cells.
    Takai N; Tanaka R; Yoshida S; Hara N; Saito T
    Cancer Res; 1988 Apr; 48(8):2047-52. PubMed ID: 3258182
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Lymphokine-activated killer (LAK) therapy for advanced renal cell carcinoma: clinical study on arterial LAK therapy and experimental study on LAK cell activity].
    Hayakawa M
    Hinyokika Kiyo; 1992 Nov; 38(11):1311-8. PubMed ID: 1485587
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Influence of T cells on the expression of lymphokine-activated killer cell activity and in vivo tissue distribution.
    Maghazachi AA; Goldfarb RH; Herberman RB
    J Immunol; 1988 Dec; 141(11):4039-46. PubMed ID: 2846699
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A randomized phase II trial of continuous infusion interleukin-2 or bolus injection interleukin-2 plus lymphokine-activated killer cells for advanced renal cell carcinoma.
    Weiss GR; Margolin KA; Aronson FR; Sznol M; Atkins MB; Dutcher JP; Gaynor ER; Boldt DH; Doroshow JH; Bar MH
    J Clin Oncol; 1992 Feb; 10(2):275-81. PubMed ID: 1732429
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Scintigraphy with In-111 labeled lymphokine-activated killer cells of malignant brain tumor.
    Itoh K; Sawamura Y; Hosokawa M; Kobayashi H
    Radiat Med; 1988; 6(6):276-81. PubMed ID: 2854899
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Enhanced human lymphokine-activated killer cell function after brief exposure to granulocyte-macrophage-colony stimulating factor.
    Baxevanis CN; Dedoussis GV; Papadopoulos NG; Missitzis I; Beroukas C; Stathopoulos GP; Papamichail M
    Cancer; 1995 Oct; 76(7):1253-60. PubMed ID: 8630906
    [TBL] [Abstract][Full Text] [Related]  

  • 34. In vivo boosting of lung natural killer and lymphokine-activated killer cell activity by interleukin-2: comparison of systemic, intrapleural and inhalation routes.
    Flexman JP; Manning LS; Robinson BW
    Clin Exp Immunol; 1990 Oct; 82(1):151-6. PubMed ID: 2208789
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Endogenous and adoptively transferred A-NK and T-LAK cells continuously accumulate within murine metastases up to 48 h after inoculation.
    Hokland M; Kjaergaard J; Kuppen PJ; Nannmark U; Agger R; Hokland P; Basse P
    In Vivo; 1999; 13(3):199-204. PubMed ID: 10459491
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of tumor irradiation on the uptake of lymphokine-activated killer cells in a murine tumor model.
    Munshi NC; Williams JR
    Cancer Res; 1994 Apr; 54(7):1657-9. PubMed ID: 8137277
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Lymphocyte migration to tumors after hyperthermia and immunotherapy.
    Midis GP; Fabian DF; Lefor AT
    J Surg Res; 1992 May; 52(5):530-6. PubMed ID: 1619922
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Phase I trial of intraperitoneal recombinant interleukin-2/lymphokine-activated killer cells in patients with ovarian cancer.
    Stewart JA; Belinson JL; Moore AL; Dorighi JA; Grant BW; Haugh LD; Roberts JD; Albertini RJ; Branda RF
    Cancer Res; 1990 Oct; 50(19):6302-10. PubMed ID: 2205379
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Lymphokine-activated killer (LAK) therapy for metastatic renal cell carcinoma].
    Nakano E
    Hinyokika Kiyo; 1992 Nov; 38(11):1305-9. PubMed ID: 1485586
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Adoptive immunotherapy of a rat glioma using lymphokine-activated killer cells and interleukin 2.
    Tzeng JJ; Barth RF; Clendenon NR; Gordon WA
    Cancer Res; 1990 Jul; 50(14):4338-43. PubMed ID: 2364388
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.